BioSpace News Archive

Guidance for professionals and individuals who are struggling with depression and anxiety.

Chaired by award-winning dermatologist Seth B. Forman, MD, of ForCare Medical Group in Tampa, FL, the study will assess weekly bermekimab therapy to reduce inflammatory skin lesions, itch, and pain in patients suffering from eczema.

53% of Patients Achieve Undetectable or BLOQ HDV RNA at Week 24

Creates First Industry Relationship to Pair Earth Observation with Global Communications Infrastructure

The owner of Denver Vein Center, a top vein treatment center in Colorado since 2004, announces a new, integrated approach to patient health care with the launch of EVEXIAS Medical Denver - Colorado’s exclusive provider of EvexiPEL™,

Dr. David Shafer of Shafer Plastic Surgery and Laser Center in midtown Manhattan, announces the acquisition of the Vbeam® Prima™ Laser System by Candela, an advanced 595 nm pulsed dye laser (PDL).

Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX: RVX) today announces that it has scheduled a conference call and webcast to supplement the presentation of BETonMACE results to be made during the American Heart Association’s (“AHA”) annual conference.

Ionis Pharmaceuticals, Inc., the leader in antisense therapeutics, announced that management will present a company overview at the following investor conferences

Concert Pharmaceuticals, Inc. announced that it will participate at the following upcoming investor conferences

bluebird bio, Inc. and Forty Seven, Inc. announced that they have entered into a research collaboration to pursue clinical proof-of-concept for Forty Seven’s novel antibody-based conditioning regimen, FSI-174 plus magrolimab, with bluebird’s ex vivo lentiviral vector hematopoietic stem cell gene therapy platform.